These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 29611028)

  • 1. Comparison of Immunohistochemistry and Direct Sequencing Methods for Identification of the BRAF
    Kim JK; Seong CY; Bae IE; Yi JW; Yu HW; Kim SJ; Won JK; Chai YJ; Choi JY; Lee KE
    Ann Surg Oncol; 2018 Jun; 25(6):1775-1781. PubMed ID: 29611028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific immunohistochemical detection of the BRAF V600E mutation in primary and metastatic papillary thyroid carcinoma.
    Zhu X; Luo Y; Bai Q; Lu Y; Lu Y; Wu L; Zhou X
    Exp Mol Pathol; 2016 Feb; 100(1):236-41. PubMed ID: 26795218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of immunohistochemistry for the detection of the BRAF(V600E) mutation in papillary thyroid carcinoma: comparative analysis with three DNA-based assays.
    Ilie MI; Lassalle S; Long-Mira E; Bonnetaud C; Bordone O; Lespinet V; Lamy A; Sabourin JC; Haudebourg J; Butori C; Guevara N; Peyrottes I; Sadoul JL; Bozec A; Santini J; Capper D; von Deimling A; Emile JF; Hofman V; Hofman P
    Thyroid; 2014 May; 24(5):858-66. PubMed ID: 24417277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Value of immunohistochemistry in the detection of BRAF(V600E) mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma.
    Zimmermann AK; Camenisch U; Rechsteiner MP; Bode-Lesniewska B; Rössle M
    Cancer Cytopathol; 2014 Jan; 122(1):48-58. PubMed ID: 24039206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VE1 immunohistochemistry is an adjunct tool for detection of BRAF
    Rashid FA; Tabassum S; Khan MS; Ansari HR; Asif M; Sheikh AK; Sameer Aga S
    J Clin Lab Anal; 2021 Feb; 35(2):e23628. PubMed ID: 33305405
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.
    Bullock M; O'Neill C; Chou A; Clarkson A; Dodds T; Toon C; Sywak M; Sidhu SB; Delbridge LW; Robinson BG; Learoyd DL; Capper D; von Deimling A; Clifton-Bligh RJ; Gill AJ
    Endocr Relat Cancer; 2012 Dec; 19(6):779-84. PubMed ID: 22997209
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunohistochemical detection of the BRAF V600E mutation in papillary thyroid carcinoma. Evaluation against real-time polymerase chain reaction.
    Paja Fano M; Ugalde Olano A; Fuertes Thomas E; Oleaga Alday A
    Endocrinol Diabetes Nutr; 2017 Feb; 64(2):75-81. PubMed ID: 28440781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of BRAF V600E detection approaches in papillary thyroid carcinoma.
    Chen D; Qi W; Zhang P; Zhang Y; Liu Y; Guan H; Wang L
    Pathol Res Pract; 2018 Feb; 214(2):303-307. PubMed ID: 29254799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemistry is a feasible method to screen BRAF V600E mutation in colorectal and papillary thyroid carcinoma.
    Zhang X; Wang L; Wang J; Zhao H; Wu J; Liu S; Zhang L; Li Y; Xing X
    Exp Mol Pathol; 2018 Aug; 105(1):153-159. PubMed ID: 30009773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Value of the detection of
    Zhao H; Guo HQ; Zhang ZH; Cao J; Zhao LL; Sun Y; Wang C; Xiao T
    Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jan; 54(1):18-22. PubMed ID: 30704164
    [No Abstract]   [Full Text] [Related]  

  • 11. Immunohistochemistry is highly sensitive and specific for detecting the BRAF V600E mutation in papillary thyroid carcinoma.
    Sun J; Zhang J; Lu J; Gao J; Lu T; Ren X; Duan H; Liang Z
    Int J Clin Exp Pathol; 2015; 8(11):15072-8. PubMed ID: 26823846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of droplet digital PCR and direct Sanger sequencing for the detection of the BRAF
    Wang Z; Sun K; Jing C; Cao H; Ma R; Wu J
    J Clin Lab Anal; 2019 Jul; 33(6):e22902. PubMed ID: 31021028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
    Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
    Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer.
    Martinuzzi C; Pastorino L; Andreotti V; Garuti A; Minuto M; Fiocca R; Bianchi-Scarrà G; Ghiorzo P; Grillo F; Mastracci L
    Endocrine; 2016 Sep; 53(3):672-80. PubMed ID: 26296380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunohistochemistry for BRAF(V600E) antibody VE1 performed in core needle biopsy samples identifies mutated papillary thyroid cancers.
    Crescenzi A; Guidobaldi L; Nasrollah N; Taccogna S; Cicciarella Modica DD; Turrini L; Nigri G; Romanelli F; Valabrega S; Giovanella L; Onetti Muda A; Trimboli P
    Horm Metab Res; 2014 May; 46(5):370-4. PubMed ID: 24570209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The immunocytochemical expression of VE-1 (BRAF V600E-related) antibody identifies the aggressive variants of papillary thyroid carcinoma on liquid-based cytology.
    Straccia P; Brunelli C; Rossi ED; Lanza P; Martini M; Musarra T; Lombardi CP; Pontecorvi A; Fadda G
    Cytopathology; 2019 Sep; 30(5):460-467. PubMed ID: 30875124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF Immunohistochemistry Using Clone VE1 is Strongly Concordant with BRAF(V600E) Mutation Test in Papillary Thyroid Carcinoma.
    Pyo JS; Sohn JH; Kang G
    Endocr Pathol; 2015 Sep; 26(3):211-7. PubMed ID: 25957797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinoma.
    Wobker SE; Kim LT; Hackman TG; Dodd LG
    Cancer Cytopathol; 2015 Sep; 123(9):531-9. PubMed ID: 26080065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.
    Zagzag J; Pollack A; Dultz L; Dhar S; Ogilvie JB; Heller KS; Deng FM; Patel KN
    Surgery; 2013 Dec; 154(6):1199-204; discussion 1204-5. PubMed ID: 23931769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.